Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 July 2020 | Story Andre Damons | Photo Supplied
Prof Felicity Burt and Prof Paul Grobler from the UFS.

Three scientists from the University of the Free State (UFS), together with authors from other institutions, are part of an international COVID-19 study published in an international peer-reviewed scientific journal recently. 

Prof Paul Grobler, Academic Head of Department: Genetics; Prof Felicity Burt, researcher from the Division of Virology, Faculty of Health Sciences and the NHLS, and SARChI (South African Research Chairs Initiative) Research Chair in vector-borne and zoonotic diseases; as well as Prof Trudy Turner from the University of Wisconsin-Milwauwkee, but also an affiliated professor in the Department of Genetics at the UFS, are co-authors of the paper that appeared in Plos One. The study is titled: ACE2 and TMPRSS2 variation in savanna monkeys (Chlorocebus spp.): Potential risk for zoonotic/anthroponotic transmission of SARS-CoV-2 and a potential model for functional studies.

 The paper follows an initiative of Prof Chris Schmitt at Boston University with researchers affiliated to the University of California, Los Angeles, Rutgers University, the Polish Academy of Sciences, the Ministry of Health of the Russian Federation, the University of Antwerp, the Wake Forest School of Medicine, and the University of Wisconsin-Milwaukee. The team used the opportunity presented by previously sequenced genomes to screen for variation in the genes associated with susceptibility to infection with SARS-CoV-2.

Concerns about animal welfare and conservation issues

Prof Grobler, who has been studying vervet monkeys from a conservation perspective for two decades, says considering the impact of COVID-19 on the country, he feels that any aspect that might potentially help to understand the progression and transmission of the disease, as well as unexpected risks – however small – should be investigated. 
“Since wildlife management is my field, I am of course also concerned about the potential animal welfare and conservation issues involved.  It should, however, be emphasised that while SARS-CoV-2 infection in vervet monkeys has now been shown to be genetically possible, there is no proof of it actually happening in the wild yet.” 

“I am sure that much work on COVID-19 and vervets will follow internationally, but this is the first study to describe variation at the genes linked to susceptibility,” says Prof Grobler. 

Because of his previous work with vervet monkeys in South Africa and further afield, Prof Grobler was invited by Prof Schmitt to contribute to the manuscript.

“I made some suggestions from a conservation perspective, based on my interpretations and also recent international work that have shown that many primate species may be at risk for SARS-CoV-2 infection and are potentially vulnerable to COVID-19. I also felt that some aspects of the paper would be greatly improved with input from a South African expert in zoonotic disease to add to the genetic and conservation perspectives, and I therefore requested that Prof Burt also be approached.”

Potential for non-human primates infection

Prof Burt, whose research interests and expertise include the investigation of viruses of zoonotic origin, and/or those transmitted by mosquitoes and ticks that impact human and/or animal well-being – using a One Health approach – says the study was a collaborative effort between scientists with expertise in a wide range of disciplines, including biological anthropology, genetics, primatology, molecular biology, and virology.

“The concept of One Health encourages collaboration between multiple disciplines, promoting the concept that the interaction between humans, animals, and the environment has an impact on the health of people, animals, plants, and the environment. The outcome is an exciting study that incorporates knowledge from each discipline to investigate the potential susceptibility of non-human primate populations to SARS-CoV-2.” 

“The research suggests that there is potential for novel SARS-CoV-2 to infect non-human primates, and that surveillance of non-human primates living in close proximity to human populations is not only warranted, but is actually important for defining risk to both humans and animals,” says Prof Burt. 

According to her, the majority of recently emerged viruses, including SARS-CoV-2, were zoonotic in origin. The close proximity of humans and wild non-human primates provides potential for cross-species transmission of pathogens; for some endangered species, this could have devastating effects. Similarly, identifying if non-human primates have the potential to act as intermediate hosts for pathogens with significant public health implications, would be important for understanding zoonotic transmission.

“Novel viruses are continually emerging, and we need to be prepared. A multidisciplinary approach to understanding interactions at the wildlife-human interface will be essential for the prevention of future outbreaks.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept